Job Title: Senior Analyst, Financial Planning & Analysis
FLSA Status: Exempt
Position Overview:
We are looking for an enthusiastic and committed team member to join our FP&A (Financial Planning & Analysis) department in our London, UK Office. Insulet International supports the rapid development of our commercial activities outside of the United States. We expect to continue our exceptional growth trajectory in 2023, with exciting initiatives such as new product launch and new ERP implementation.
Part of Finance, the International FP&A team manages the budgeting, forecasting, and analytical processes for 23 countries across Europe, the Middle East (EMEA), Canada, and Australia. We are a team of nine based across London & Paris. Our mission is to support our stakeholders in setting, achieving, and measuring performance against operational and financial ambitions, bringing them robust financial expertise combined with an active business partnering mindset.
As the Sr. FP&A Analyst, DACH, you will be responsible for ensuring monthly performance and day-to-day business support for our DACH (Germany, Austria & Switzerland) and other functions in our organizations, supporting revenues, Operating Expenses, and Headcount.
Responsibilities:
Required Leadership/Interpersonal Skills & Behaviours:
Required Skills and Competencies:
Education and Experience:
Additional Information:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.
We are looking for highly motivated, performance-driven individuals to be a part of our expanding team. We do this by hiring amazing people guided by shared values who exceed customer expectations. Our continued success depends on it!
Please read our Privacy Notice to learn how Insulet handles your personal information when you apply for a vacancy with us here.